A method for generating a plurality of diverse camelid antibodies to cover functional epitopes of the target with high-resolution. Also provided is a method for generating camelid antibodies.

Disclosed herein is a novel class of isolated binding molecules including monoclonal antibodies that targets a broadly conserved epitope within the marburgvirus species. Certain aspects provide an effective treatment option for hemorrhagic fever caused by marburgviruses.

Provided herein are antibodies binding to LILRB1 and the uses of the antibodies in detecting and treating cancer and autoimmune diseases.

Disclosed are an IL-5 binding molecule, and a preparation method and use thereof. The binding molecule includes the following complementarity determining regions: an amino acid sequence of CDR1 selected from any one of sequences as set forth in SEQ ID NOs. 43-49; an amino acid sequence of CDR2 selected from any one of sequences as set forth in SEQ ID NOs. 50-56; and an amino acid sequence of CDR3 selected from any one of sequences as set forth in SEQ ID NOs. 57-62. The binding molecule is capable of specifically binding to IL-5, and effectively blocking the cell proliferation induced by IL-5.

This disclosure provides isolated or recombinant polypeptides that are useful to vaccinate individuals suffering from chronic/recurrent biofilm disease or as a therapeutic for those with an existing infection. The individual's immune system will then naturally generate antibodies which prevent or clear these bacteria from the host by interfering with the construction and or maintenance of a functional protective biofilm. Alternatively, antibodies to the polypeptides can be administered to treat or prevent infection. Bacteria that cannot form functional biofilms are more readily cleared by the remainder of the host's immune system and/or traditional antibiotics.

Methods, devices and systems for delivery of an anti-PD-1 or an anti-PD-L1 therapeutic agent to the lymphatic system for treating cancer in a patient are described.

The present invention relates, in part, to agents that bind PD-L1 and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the PD-L1 targeting moiety and their use in the treatment of various diseases.

The present application provides an isolated PD-L1 binding molecule, specifically, an isolated PD-L1 single-domain antibody or an antigen-binding fragment thereof. The present invention also provides a nucleic acid encoding the isolated PD-L1 binding molecule, an expression vector or host cell comprising the nucleic acid, and a pharmaceutical composition or kit comprising the PD-L1 binding molecule.

An antibody or antigen-binding fragment specifically binds to human programmed cell death ligand-1 (PD-L1). The antibody or antigen-binding fragment is able to enhance the function of T cells and upregulate a T cell-mediated immune response. The antibody or the antigen-binding fragment is useful for the treatment of diseases, e.g. tumor, associated with aberrant expression of PD-L1 and/or dysfunction of T cells.

Provided are methods of treating cancer or increasing, enhancing, or stimulating an immune response with non-competitive, agonist anti-OX40 antibodies and antigen-binding fragments thereof that bind to human OX40 (ACT35, CD134, or TNFRSF4), in combination with an anti-TIM3 antibody or antigen binding fragment thereof.